A comparison of frailty classifications of older patients with cancer was conducted to evaluate their performance in predicting outcomes.
Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.
Oral cannabinoids can ease chronic pain and chemotherapy-related nausea, but researchers cite risks, as well.
MABp1 (Xilonix) is an interleukin 1_-targeting antibody associated with antitumor activity and relief of debilitating symptoms in patients with advanced colorectal cancer. In this ongoing phase 3 clinical trial, its impact on other debilitating symptoms in this population was evaluated.
Moderate but not vigorous activity proved beneficial for patients with metastatic colorectal cancer.
Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.
First-in-class drugs are fast-tracked while follow-on drugs can take up to 15 years to be approved by the FDA.
Findings are presented from an open-label NETTER-1 clinical trial evaluating the efficacy and safety of 177Lu-Dotatate in patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue.
Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.
In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.
Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.
Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.
Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.
Cancer mortality rates in the United States have dropped, according to a new ACS report.
A cohort of participants in the MAP.3 trial completed the MENQOL questionnaire, and the findings shed light on the influence of changes in menopause-specific quality of life on aromatase inhibitor adherence in women at high risk for breast cancer.
Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.
Features mainly linked to mammographic breast density are key in influencing a classification of normal.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.
Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.
Findings at 6 and 12 months after treatment for advanced head and neck cancer indicate a higher risk of recurrences for those reporting cachexia after their treatment.
Many patients can still experience UA-RINV despite prophylactic therapy; therefore, researchers explored the effectiveness and safety of dual prophylactic therapy with an NK1 receptor antagonist and a 5-HT3 receptor antagonist.
Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.
An evaluation of the association of tissue factor, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE helps determine their predictive value for patients at high risk.
A comparison of administering the influenza vaccine concurrently with chemotherapy with that of administration within the cytopenic period during 3-week chemotherapy cycles determined which schedule was the optimal timing for vaccination administration in this group.
High pretreatment uric acid may be a clinical biomarker for lung metastasis.
Researchers sought to evaluate the incidence of cancer-related cognitive impairment in patients with breast cancer in a large prospective, longitudinal, nationwide study. These findings address limitations in previous research.
Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.
New Oral Therapy Shows Promise Against Neurofibromatosis Type 1-Related Plexiform Neurofibromatomas in ChildrenJanuary 03, 2017
In this clinical trial, researchers determined the safety and efficacy of selumetinib, a selective MEK inhibitor, in children with NF1-related neurofibromas.
Melanoma incidence varies by region, and many states have experienced an increase.
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy
- Role of Oncology Nurse Navigators Has Evolved and Expanded in 5 Years
- Frailty Classifications Associated With Prognosis Among Older Patients
- Beach Umbrella Not Enough for Protection from UV Rays
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|